Last updated: March 23, 2026
What is NDC 70010-0005?
NDC 70010-0005 is the code for Voretigene neparvovec (Luxturna), a gene therapy developed by Spark Therapeutics (a subsidiary of Roche). It targets inherited retinal dystrophy caused by biallelic RPE65 gene mutations. Approved by the FDA in December 2017, it represents a first-in-class gene therapy for a rare genetic form of blindness.
Market Overview
Target Population
The drug treats a rare condition, with estimates of approximately 1,000 to 2,000 diagnosed patients in the U.S. (according to the Hereditary Eye Disease Clinic at the Casey Eye Institute).
Market Size
Global estimates project the rare retinal dystrophy treatment market to grow from USD 350 million in 2022 to USD 700 million by 2027, driven by increasing diagnosis rates and expanding approval in additional countries.
Competitive Landscape
- Branch of the gene therapy sector targeting inherited retinal diseases (IRDs).
- Competitors include ADVM-022 (Adverum Biotechnologies), though no current direct alternatives for RPE65 mutations are FDA-approved aside from Luxturna.
- Limited commercial competitors due to the specialized nature of the therapy.
Key Market Dynamics
- High unmet need due to the rarity and severity of the condition.
- Reimbursement challenges owing to its USD 850,000 list price per treatment.
- Growing awareness and diagnostics influence market growth.
- Potential expansion of indications for other genetic retinal disorders.
Price Analysis
Current Pricing
- The U.S. wholesale acquisition cost (WAC) for Luxturna is USD 850,000 per eye, with treatment involving two surgeries for bilateral cases.
- The full treatment cost totals USD 1.7 million for both eyes.
Reimbursement Landscape
- Payers scrutinize high upfront costs; however, some coverage agreements and outcomes-based arrangements are emerging.
- Spectra of payment models include installment payments and outcomes-based reimbursement to facilitate access and minimize payer risk.
Price Trends & Projections
| Year |
Estimated Average Price (USD) |
Comments |
| 2022 |
USD 850,000 per eye |
Current list price |
| 2023 |
USD 820,000 per eye |
Expected slight reduction for competitive reasons or negotiations |
| 2024 |
USD 800,000 per eye |
Anticipated further negotiations or competition influence |
| 2025 |
USD 750,000 per eye |
Potential price reductions due to fixed-market saturation and value-based payment models |
Future Pricing & Market Strategies
- Affordability measures, including outcomes-based agreements, may reduce initial list prices.
- Off-label use and expansion of indications could influence price stability.
- Entry into international markets with different reimbursement policies may lead to lower prices globally.
Regulatory and Policy Impact
- Price regulation proposals and government negotiations, particularly in countries like Canada and European nations, could exert downward pressure.
- Value-based pricing models are increasingly standard for gene therapies, emphasizing long-term outcomes over list price.
Key Takeaways
- NDC 70010-0005 (Luxturna) is the only FDA-approved gene therapy for RPE65 mutation-associated retinal dystrophy.
- The current price is USD 850,000 per eye, totaling USD 1.7 million for bilateral treatment.
- The global market for inherited retinal disease therapies is expected to double to USD 700 million by 2027.
- Price reductions are anticipated through negotiations, outcome-based models, and market expansion.
- Entry into international markets may pressure prices downward due to varying reimbursement policies.
FAQ
1. How does Luxturna’s price compare to other gene therapies?
Luxturna’s USD 850,000 list price per eye is among the highest for approved gene therapies, comparable to Zolgensma (for spinal muscular atrophy) at USD 2.1 million per dose, but higher than therapies like Kymriah (USD 475,000).
2. What factors influence reimbursement decisions for Luxturna?
Reimbursement hinges on demonstrated clinical benefit, cost-effectiveness analyses, and value-based payment agreements aimed at long-term outcomes.
3. Are there prospects for price reductions?
Yes. Future negotiations, market competition, expanded indications, and international price regulations could lower prices over time.
4. How does the prevalence of RPE65 mutation affect market growth?
Limited patient population restricts market size, but increased genetic screening raises diagnosis rates, expanding potential treated patients.
5. Could emerging therapies impact Luxturna’s pricing?
Potential competitors or alternative delivery methods could pressure prices, though currently, no direct biosimilar or generic options exist.
References
- Food and Drug Administration (FDA). (2017). FDA approves novel gene therapy to treat patients with inherited retinal disease.
- Biocompare. (2022). Global gene therapy market size forecast.
- IQVIA. (2023). Gene and cell therapy market analysis.
- NYU Langone. (2023). Overview of inherited retinal dystrophies and treatment options.
- Statista. (2022). Global market projections for retinal disease therapies.
[1] FDA. (2017). FDA approves Luxturna for inherited blindness.
[2] Biocompare. (2022). Gene therapy market size forecast.
[3] IQVIA. (2023). Market analysis for gene and cell therapies.
[4] NYU Langone. (2023). Retinal dystrophy clinical overview.
[5] Statista. (2022). Retinal disease therapy market projection.
